EU panel backs approval of Aegerion's cholesterol drug lomitapide

06/3/2013 | American City Business Journals

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Aegerion Pharmaceuticals' lomitapide for treatment of patients with homozygous familial hypercholesterolemia. If approved in Europe, the drug will be marketed under the name Lojuxta. Lomitapide was approved in the U.S. last year with the brand name Juxtapid.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA